恩替卡韦联合阿德福韦酯治疗高病毒载量慢性乙型肝炎的疗效观察

张文; 余建国; 朱贵忠; 赵詹东; 王晓伟

doi:10.3969/j.issn.1001-5256.2014.11.019

恩替卡韦联合阿德福韦酯治疗高病毒载量慢性乙型肝炎的疗效观察

DOI: 10.3969/j.issn.1001-5256.2014.11.019

1. 襄阳市第一人民医院肝病内科
2. 襄阳市第一人民医院检验科

详细信息

中图分类号: R512.62
计量
- 文章访问数: 3000
- HTML全文浏览量: 7
- PDF下载量: 524
- 被引次数: 0
出版历程
- 收稿日期: 2014-02-18
- 出版日期: 2014-11-20

Clinical efficacy of entecavir combined with adefovir in chronic hepatitis B patients with high viral load

Department of Liver Medicine, The First People's Hospital of Xiangyang

摘要

摘要:
目的探讨恩替卡韦与阿德福韦酯联合治疗高病毒载量慢性乙型肝炎(CHB)的疗效及安全性。方法收集2008年12月至2011年12月收治的高病毒载量CHB初治患者80例,随机分为观察组和对照组各40例。对照组采用恩替卡韦(ETV)治疗,观察组采用ETV联合阿德福韦酯(ADV)治疗。观察2组患者治疗前和治疗3、6、12、24个月时的HBV DNA载量、HBsAg或HBeAg血清学转换、ALT复常及不良反应情况。计量资料2组间比较采用两独立样本t检验;计数资料2组间比较用χ2检验。结果观察组6、12、24个月时的HBV DNA载量(拷贝/ml)的对数值(3.4±0.4、2.6±0.3、1.2±0.4)比同期对照组降低程度更明显(3.7±0.3、2.9±0.4、1.6±0.7)(t值分别为3.339、5.657、2.806,P值均<0.05)。观察组治疗12、24个月时HBV DNA阴转率(87.5%、95.0%)、HBeAg转阴率(80.0%、90.0%)明显高于对照组(70.0%、77.5%;55.0%、70.0%)(P值均<0.05)。观察组治疗24个月时HBeAg血清学转换率及...
- 肝炎,乙型,慢性 /
- 药物疗法,联合 /
- 恩替卡韦 /
- 阿德福韦酯
Abstract:
Objective To investigate the efficacy and safety of entecavir (ETV) combined with adefovir (ADV) in chronic hepatitis B (CHB) patients with high viral load. Methods Eighty CHB patients with high viral load who were admitted to our hospital from December2008 to December 2011 were equally and randomly divided into observation group and control group. The control group was given ETV, while the observation group was treated with ETV combined with ADV. HBV DNA load, HBsAg or HBeAg seroconversion, alanine aminotransferase (ALT) normalization, and adverse reactions before and after 3, 6, 12, and 24 months of treatment were evaluated. Comparison of continuous data between the two groups was made by independent- samples t test, and comparison of categorical data was made by chi- square test. Results Compared with the control group, the observation group had significantly lower HBV DNA load after 6, 12, and 24 months of treatment (3.7 ±0.3 vs3.4 ±0.4 log copies/ml, t =3.339, P<0.05;2.9 ±0.4 vs2.6 ±0.3 log copies/ml, t =5.657, P <0.05;1.6 ±0.7 vs1.2 ±0. 4 log copies /ml, t = 2. 806, P < 0. 05) . The HBV DNA clearance rate and HBeAg clearance rate in observation group were significantly higher than those in control group after 12 months of treatment (87. 5% vs 70. 0%, P < 0. 05; 80. 0% vs 55. 0%, P < 0. 05) and 24 months of treatment (95. 0% vs 77. 5%, P < 0. 05; 90. 0% vs 70. 0%, P < 0. 05) . The observation group had significantly higher HBeAg seroconversion rate and ALT normalization rate than the control group after 24 months of treatment (77. 5% vs 50. 0%, P < 0. 05; 82. 5% vs 55. 0% P <0. .="" during="" the="" there="" was="" no="" significant="" difference="" in="" incidence="" of="" adverse="" reactions="" between="" two="" groups="" p="">0. 05) , but the observation group had a significantly lower viral breakthrough rate than the control group (0 vs 10. 0%, P < 0. 05) . Conclusion For CHB patients with high viral load, ETV combined with ADV has strong antiviral activity, reduces drug resistance and poor response, and shows better long- term clinical efficacy than ETV alone, suggesting that it is a safe and reliable therapy.
- hepatitis B, chronic /
- drug therapy, combination /
- entecavir /
- adefovir

HTML全文

参考文献(9)

[1]LOK AS.HBV treatment in dications and efficacy of approved nuclcoside/nucleotide inhibitors[C/OL]//EASL-AASLD-APASL-ALEH-IASL Conference:hepatitis B and C virus resistance to antiviral therapies, Paris, 2008.http://www.easl.ch/hepatitisconference.

[2]WU JM, XIE XS, HE JQ.Adefovir dipivoxi combined with thymosinα1 in treatment of chronic hepatitis B patients with high viral loads:a clinical analysis of 110 cases[J].Chin J Clin Infect Dis, 2012, 5 (6) :355-357. (in Chinese) 吴建明, 谢新生, 何剑琴.阿德福韦酯联合胸腺肽α1治疗高病毒载量慢性乙型肝炎110例临床分析[J].中华临床感染病杂志, 2012, 5 (6) :355-357.

[3]Chinese Society of Infectious Diseases and Parasitology, Chinese Society of Hepatology, Chinese Medical Association.Prevention and treatment of viral hepatitis[J].Chin J Infect Dis, 2001, 19 (1) :56-62. (in Chinese) 中华医学会传染病与寄生虫病学分会、肝病学分会.病毒性肝炎防治方案[J].中华传染病杂志, 2001, 19 (1) :56-62.

[4] LI QF, LIU YN, YANG HL, et al.Effects of adefovir dipivoxil combined with lamivudine on HBV DNA duplication and T cell subsets in chronic hepatitis B patients[J].Int J Virol, 2014, 21 (4) :168-171. (in Chinese) 黎秋芬, 刘亚南, 杨红丽, 等.阿德福韦酯联合拉米夫定对CHB患者HBV DNA复制和T细胞亚群的影响[J].国际病毒学杂志, 2014, 21 (4) :168-171.

[5]WANG F, WANG H, SHEN H, et al.Evolution of hepatitis B virus polymerase mutations in a patient with HBeAg-positive chronic hepatitis B virus treated with sequential monotherapy and add-onnucleoside/nucleotide analogues[J].Clin Ther, 2009, 31 (2) :360-366.

[6]ZHU BJ.Clinical study on adefovir and lamivudine in treatment of chronic type B hepatitis patients with lamivudine medicine endurance[J].Chin J Postgraduates Med, 2010, 33 (4) :22-24. (in Chinese) 朱宝剑.阿德福韦酯联合拉米夫定治疗拉米夫定耐药慢性乙型肝炎患者的临床研究[J].中国医师进修杂志, 2010, 33 (4) :22-24.

[7]FAN P, CHEN SX, HE WX, et al.Efficacy of entecavir combined with adefovir dipivoxil for double-resistant strains:an analysis of22 patients with chronic hepatitis B[J].Herald Med, 2012, 31 (4) :432-433. (in Chinese) 范平, 陈仕祥, 何维新, 等.恩替卡韦联合阿德福韦酯治疗双重耐药慢性乙型肝炎22例[J].医药导报, 2012, 31 (4) :432-433.

[8]HE Q, WANG S, ZHAO LS.Efficacy of adefovir dipivoxil combined with entecavir in treatment of infection with multidrug-resistant HBV:a report of one case[J/CD].Chin J Liver Dis:Electronic Edition, 2010, 2 (4) :28-29. (in Chinese) 何清, 王松, 赵连三.阿德福韦酯联合恩替卡韦治疗HBV复杂耐药感染的启示——附一例病例报告[J/CD].中国肝脏病杂志:电子版, 2010, 2 (4) :28-29.

[9]CHEN WY, CHEN LC.Clinical study on anti-HBV effect of adefovir dipivoxil combined with lamivudine[J].J Pract Med, 2008, 24 (14) :2492-2494. (in Chinese) 陈文郁, 陈兰春.阿德福韦酯与拉米夫定联合抗乙型肝炎病毒效果的临床研究[J].实用医学杂志, 2008, 24 (14) :2492-2494.

施引文献

资源附件(0)

访问统计